… Recent genetic analysis using next-generation sequencing (NGS) vastly improved the
understanding of molecular mechanism of hematological malignancies. Many molecular targeting …

… urgency and importance to develop immunoproteasome-selective inhibitors with less
toxicity for the treatment of hematologic malignancies, nervous system diseases and immune …

… In summary, a β5i-selective inhibitor requires bulky hydrophobic amino acids, like Trp or
Phe, at the P1 site and small polar groups in P3, while a β1i-selective inhibitor must possess …

… hematological malignancies. This inspired the development of novel agents that selectively
… the new development of SINE inhibitiors in hematological malignancies. Selinexor (KPT-330…

… for the treatment of hematological malignancies. Forty of them … are used to treat hematological
malignancies, which make … in the treatment of hematological malignancies, which was …

… -molecule CDK inhibitors (CDKIs) have shown most promise against hematologic malignancies.
… CDKIs are discussed from a hematologic malignancy perspective. Additionally, novel …

… inhibitors (FTIs) represent a new class of signaling inhibitors that is emerging in the clinical
arena of hematologic malignancies … potent and selective competitive inhibitors of intracellular …

… gaps in our current armamentaria against hematologic malignancies. Lessons learned thus
far … the potential to further improve clinical outcomes in multiple hematologic malignancies. …

… Karyopherins are crucial controllers of cell growth and are overexpressed in numerous
hematologic malignancies, in some of which they are recognized as a poor prognostic factor.46, …

… of hematological malignancies; consequently, their targeting (alone or in combination)
may be highly favorable in therapeutic interventions against hematological malignancies. …